<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2039">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824391</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAL00620-EU02-PK537-3</org_study_id>
    <nct_id>NCT04824391</nct_id>
  </id_info>
  <brief_title>Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19</brief_title>
  <official_title>Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Institutes of Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erciyes University Scientific Research Projects Coordination</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Institutes of Turkey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine the efficacy, immunogenicity and safety of two different&#xD;
      strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to&#xD;
      demonstrate the efficacy and safety in prophylaxis of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum IgG antibody levels specific for the SARS-CoV- 2 rS protein antigen(s)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibodies from microneutralization assay</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood levels of cytokines: TNF-α, IFN-γ, IL-2, IL-4, IL-5 and IL-6</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>3 mcg/0.5 ml Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mcg/0.5 ml Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ERUCOV-VAC 3 µg/0.5 ml Vaccine</intervention_name>
    <description>Two IM applications on Days 1 and 28</description>
    <arm_group_label>3 mcg/0.5 ml Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ERUCOV-VAC 6 µg/0.5 ml Vaccine</intervention_name>
    <description>Two IM applications on Days 1 and 28</description>
    <arm_group_label>6 mcg/0.5 ml Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two IM applications on Days 1 and 28</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy Caucasian origin&#xD;
&#xD;
          -  accepting not to participate in another COVID-19 vaccine study until the end of the&#xD;
             study&#xD;
&#xD;
          -  volunteers who do not plan to get a child in the next one year; the volunteer and the&#xD;
             partner should use a reliable form of contraception (abstinence, condom, birth control&#xD;
             implant, birth control pills used or IUD used by the partner) during the study for at&#xD;
             least 1 year&#xD;
&#xD;
          -  female participants of childbearing potential (defined as any female who has&#xD;
             experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral&#xD;
             tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at&#xD;
             least 12 consecutive months) must agree to be heterosexually inactive through 12&#xD;
             months after the first vaccination OR agree to consistently use any of the described&#xD;
             methods of contraception from through 12 months after the first vaccination.&#xD;
&#xD;
          -  male subjects agree to refrain from sperm donation from the time of first vaccination&#xD;
             until 3 months after last vaccination&#xD;
&#xD;
          -  participants must refrain from blood or plasma donation from the time of first&#xD;
             vaccination until 3 months after last vaccination&#xD;
&#xD;
          -  the outcome of the following examinations should be clinically insignificant: medical&#xD;
             and surgical history (hypo-, hypertension, allergy, other diseases, major surgery,&#xD;
             micturition, defecation, sleep, illness within the last 4 weeks prior to the start of&#xD;
             the trial);&#xD;
&#xD;
          -  life style and habits (consumption of alcohol, nicotine, coffee, tea, coke, special&#xD;
             diet, drug abuse) should be normal/acceptable&#xD;
&#xD;
          -  body temperature, pulse rate, blood pressure and respiratory rate should be&#xD;
             normal/acceptable.&#xD;
&#xD;
          -  laboratory examination (blood/serum examination: sodium, potassium, calcium, total&#xD;
             protein, albumin, glucose, creatinine, BUN, total bilirubin, AST, ALT, GGT, ALP,&#xD;
             haemoglobin, haematocrit, erythrocytes, Ieukocytes, platelet count; HBsAg, HIV-Ab,&#xD;
             HCV-Ab should be normal/acceptable.&#xD;
&#xD;
          -  antiSARS CoV 2 total antibody (including COVID-19 IgG and/or IgM) negative in serum.&#xD;
&#xD;
          -  body weight in relation to height and age accepted BMI range 18.5 and 32 kg/m2 - both&#xD;
             inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women with a positive blood (β-HCG) pregnancy test&#xD;
&#xD;
          -  lactating women&#xD;
&#xD;
          -  history of COVID-19 infection or showing COVID-19 infection symptoms&#xD;
&#xD;
          -  having had contact to people with known COVID-19 infection in the last 14 days&#xD;
&#xD;
          -  having fever (&gt; 37.4oC in the last 24 hours), dry cough or feeling tired and having&#xD;
             aches and pains, nasal congestion, runny nose, sore throat and diarrhea.&#xD;
&#xD;
          -  positive real time RT-PCR COVID-19 test.&#xD;
&#xD;
          -  leukemia or neoplasm in history.&#xD;
&#xD;
          -  persons with autoimmune diseases&#xD;
&#xD;
          -  allergic diathesis or any clinically significant allergic disease (i.e. asthma)&#xD;
&#xD;
          -  any condition that might impair the immune response&#xD;
&#xD;
          -  recent or current immunosuppressive medication&#xD;
&#xD;
          -  any other vaccine application 30 days before the first dose&#xD;
&#xD;
          -  presence or a history of clinically significant cardiovascular, renal, hepatic,&#xD;
             pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological,&#xD;
             psychiatric or other major diseases;&#xD;
&#xD;
          -  disruption of platelets or other blood clotting disorders, which may cause&#xD;
             contraindications to intramuscular administration&#xD;
&#xD;
          -  clinically significant illness within 4 weeks before the start of the study.&#xD;
             Especially any acute or chronic illness seizures.&#xD;
&#xD;
          -  any regular intake or administration of any prescribed systemic or topical medication&#xD;
             within 2 weeks prior to the start of the study; in the case of intake or&#xD;
             administration of any prescribed systemic or topical medication within 4 weeks before&#xD;
             the start of the study because of an insignificant illness, this should be stated in&#xD;
             the CRF.&#xD;
&#xD;
          -  intake or administration of OTC medication (including herbal remedies) which may have&#xD;
             an effect on the study according to the investigator within 2 weeks prior to the start&#xD;
             of the study&#xD;
&#xD;
          -  volunteers who received antiviral drugs, immunoglobulins or blood transfusions or any&#xD;
             other investigational drug within 4 weeks prior to the first study product&#xD;
             administration&#xD;
&#xD;
          -  concomitant intake or administration of any systemic or topical drugs (including&#xD;
             herbal remedies) on the application days&#xD;
&#xD;
          -  treatment with any investigational drug (i.e., drug not yet approved) in the last 4&#xD;
             weeks before beginning of the trial&#xD;
&#xD;
          -  medication with drugs known to alter organs or systems such as barbiturates,&#xD;
             phenothiazines, cimetidine, omeprazole etc. within the last 1 month (4 weeks)&#xD;
&#xD;
          -  donation of blood or plasma more than 450 ml within the last 2 months (8 weeks) or any&#xD;
             amount within the last month (4 weeks)&#xD;
&#xD;
          -  supine blood pressure, after resting for 5 min, higher than 140/90 or lower than&#xD;
             100/60 mmHg&#xD;
&#xD;
          -  supine pulse rate, after resting for 5 min, outside the range of 50 - 100 beats/min&#xD;
&#xD;
          -  supine respiratory rate, after resting for 5 min, outside the range of 15 - 18&#xD;
             breathings / min&#xD;
&#xD;
          -  laboratory values (appendix 5) outside normal range with clinical relevance at entry&#xD;
             examination&#xD;
&#xD;
          -  alcohol abuse i.e. regular use of more than 2 units of alcohol per day or a history of&#xD;
             alcoholism or drug/chemical abuse (one unit of alcohol equals ½ l of beer, 200 ml wine&#xD;
             or 50 ml of spirits) or recovered alcoholics&#xD;
&#xD;
          -  caffeine abuse i.e. regular use of more than 750 mg/day caffeine&#xD;
&#xD;
          -  alcoholic or methylxanthine-containing beverages or foods (coffee, tea, coke,&#xD;
             chocolate) and fruit-juice from 24 hours prior to each application&#xD;
&#xD;
          -  smoking of more than 10 cigarettes or equivalent per day, no smoking before&#xD;
             application&#xD;
&#xD;
          -  vegetarian or any special diet due to any reason&#xD;
&#xD;
          -  knowledge to have any type of parenterally transmitted hepatitis or carrier of the&#xD;
             HBsAg (HBsAg test positive)&#xD;
&#xD;
          -  HIV-Ab test positive&#xD;
&#xD;
          -  Test on anti-HCV antibodies positive&#xD;
&#xD;
          -  legal incapacity and/or other circumstances rendering the subject unable to understand&#xD;
             the nature, scope and possible consequences of the study&#xD;
&#xD;
          -  evidence of an uncooperative attitude.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Non-pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zafer Sezer, Assoc.Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Co-Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gamze Kalin Unuvar, Assist.Prof.</last_name>
    <phone>00905359872894</phone>
    <email>gamzekalinunuvar@erciyes.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erciyes University</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zafer Sezer, Assoc.Prof.</last_name>
      <phone>00903524374429</phone>
      <email>drzafersezer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmet Inal, Assist.Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mumtaz Mazicioglu, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adnan Bayram, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeynep Ture Yuce, Assist.Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Inactive</keyword>
  <keyword>Phase 2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

